Ascletis was established in 2013, and is listed on the Hong Kong Stock Exchange since 2018 (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of viral diseases, NASH/PBC, and cancer (oral cancer metabolic checkpoint and immune checkpoint inhibitors) to address unmet medical needs both in China and globally. Gannex, a wholly-owned company of Ascletis，is fully dedicated to the R&D and commercialization of new drugs in the field of NASH.
Breakthrough therapies for HBV functional cure with subcutaneously injected PD-L1 antibody - ASC22. ASC22, an immune therapy to restore HIV-specific immune responses and eventually lead to a functional cure of HIV-infecte
Global development of novel drug candidates against three different targets – FASN, THR-beta and FXR, three fixed-dose combinations for NASH and one PBC program targeting FXR.
A pipeline of oral inhibitors targeting FASN and a pipeline of oral PD-L1 inhibitors as the next generation checkpoint inhibitors.
Acne: Human sebum production requires de novo lipogenesis, which is increased in acne and suppressed by the FASN inhibitor ASC40.
Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.
Our vision is to become the most innovative world-class biomedical company. Ascletis is committed to developing and commercializing innovative drugs of NASH, cancer lipid metabolism and oral checkpoint inhibitors and viral diseases, for unmet medical needs in China and globally. Our highly talented team of researchers and professionals who passionately share in this common vision.
We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to email@example.com. We will look to match any current and upcoming openings to your area of expertise.